- Home
- KROS
as of 02-13-2026 3:46pm EST
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 584.9M | IPO Year: | 2020 |
| Target Price: | $23.00 | AVG Volume (30 days): | 266.1K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.12 - $22.55 | Next Earning Date: | 03-03-2026 |
| Revenue: | $246,718,000 | Revenue Growth: | 37798.31% |
| Revenue Growth (this year): | 6924.79% | Revenue Growth (next year): | -94.26% |
| P/E Ratio: | 10.53 | Index: | N/A |
| Free Cash Flow: | 87.1M | FCF Growth: | N/A |
AI-Powered KROS Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare KROS vs Leading Stocks
See how KROS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KROS Keros Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.